ArticleHaematologica2016
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03335670 (Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors
Who cites it
33 citing papers in PubMed, 66 citations in OpenAlex.
- 68 Ga-CXCR4-targeted PET/CT Outperforms 18 F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma : Theranostic Insights.Clinical nuclear medicine · 2026Article
- Monitoring biological effects of somatic cell genome editing.Nature reviews. Genetics · 2026Review
- The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015-2025).Theranostics · 2026Review
- CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather.Medical oncology (Northwood, London, England) · 2025Review
- Targeting the chemokine receptor CXCR4 for cancer therapies.Biomarker research · 2025Review
- On the automated radiosynthesis of pharmaceutical grade [Scientific reports · 2025Article
- CXCR4-directed endoradiotherapy with [Theranostics · 2025Article
- CXCR4 as a therapeutic target in acute myeloid leukemia.Leukemia · 2024Review
- Left Ventricular Remodelling Associated with the Transient Elevated [Molecular imaging and biology · 2024Article
- Theranostics in Hematooncology.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors.Molecules (Basel, Switzerland) · 2023Review
- CXCR4-targeted theranostics in oncology.European journal of nuclear medicine and molecular imaging · 2022Review
- Article
- In Vivo Targeting of CXCR4-New Horizons.Cancers · 2021Review
- Investigation of spleen CXCR4 expression by [EJNMMI research · 2021Article
- Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [EJNMMI research · 2020Article
- MRI and PET/MRI in hematologic malignancies.Journal of magnetic resonance imaging : JMRI · 2020Review
- Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Targeting CXCR4 in AML and ALL.Frontiers in oncology · 2020Review
- A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia originates from leukemia-initiating cells that reside in the protective bone marrow niche. CXCR4/CXCL12 interaction is crucially involved in recruitment and retention of leukemia-initiating cells within this niche. Various drugs targeting this pathway have entered clinical trials. To evaluate CXCR4 imaging in acute myeloid leukemia, we first tested CXCR4 expression in patient-derived primary blasts. Flow cytometry revealed that high blast counts in patients with acute myeloid leukemia correlate with high CXCR4 expression. The wide range of CXCR4 surface expression in patients was reflected in cell lines of acute myeloid leukemia. Next, we evaluated the CXCR4-specific peptide Pentixafor by positron emission tomography imaging in mice harboring CXCR4 positive and CXCR4 negative leukemia xenografts, and in 10 patients with active disease. [(68)Ga]Pentixafor-positron emission tomography showed specific measurable disease in murine CXCR4 positive xenografts, but not when CXCR4 was knocked out with CRISPR/Cas9 gene editing. Five of 10 patients showed tracer uptake correlating well with leukemia infiltration assessed by magnetic resonance imaging. The mean maximal standard uptake value was significantly higher in visually CXCR4 positive patients compared to CXCR4 negative patients. In summary, in vivo molecular CXCR4 imaging by means of positron emission tomography is feasible in acute myeloid leukemia. These data provide a framework for future diagnostic and theranostic approaches targeting the CXCR4/CXCL12-defined leukemia-initiating cell niche.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.